Status:
COMPLETED
Patients With Renal Impairment Undergoing CT
Lead Sponsor:
Bracco Diagnostics, Inc
Conditions:
Contrast Induced Nephropathy
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of the study is to compare the incidence of contrast induced nephrotoxicity following the administration of Isovue or Visipaque in patients with mild to moderate renal impairment who under...
Eligibility Criteria
Inclusion
- referred for MDCT of liver or peripheral CTA
- stable baseline SCr of 1.5 - 2.5 mg/dL and/or calculated CrCl of 10-60 mL/min
Exclusion
- unstable renal function
- required prophylactic drugs to receive contrast (other than hydration)
- uncontrolled diabetes
- currently on dialysis
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
End Date :
February 1 2006
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00292487
Start Date
November 1 2004
End Date
February 1 2006
Last Update
February 8 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bracco Diagnostics, Inc
Princeton, New Jersey, United States, 08543